Yüklüyor......
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
BACKGROUND: Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the potential mechanism of this resistance. METHODS: Neratinib-resistant variants of HER2-...
Kaydedildi:
| Yayımlandı: | Br J Cancer |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5344284/ https://ncbi.nlm.nih.gov/pubmed/28152547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.445 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|